Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.

被引：0
|
作者：
Cruz-Correa, Marcia
Xu, Rui-Hua
Moehler, Markus H.
Oh, Do-Youn
Kato, Ken
Spigel, David R.
Arkenau, Hendrik-Tobias
Tabernero, Josep
Zimina, Anastasia V.
Bai, Yuxian
Shi, Jianhua
Lee, Keun-Wook
Hirano, Hidekazu
Wyrwicz, Lucjan S.
Pazo Cid, Roberto
Xu, Hui
Sheng, Tao
Barnes, Gisoo
机构：
[1] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA
[2] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China
[3] Johannes Gutenberg Univ Clin, Dept Internal Med, Mainz, Germany
[4] Seoul Natl Univ Hosp, Dept Internal Med, Div Med Oncol, Seoul, South Korea
[5] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea
[6] Natl Canc Ctr, Tokyo, Japan
[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[8] Sarah Cannon Res, London, England
[9] Vall DHebron Univ Hosp & Inst Oncol VHIO, Barcelona, Spain
[10] BHI Omsk Reg Clin Oncol Dispensary, Omsk, Russia
[11] Harbin Med Univ Canc Hosp, Dept Gastrointestinal Oncol, Harbin, Peoples R China
[12] Linyi Canc Hosp, Dept Med Oncol, Linyi, Peoples R China
[13] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea
[14] Natl Canc Ctr Hosp, Dept Gastrointestinal Med Oncol, Chuo City, Japan
[15] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[16] Hosp Univ Miguel Servet, Zaragoza, Spain
[17] BeiGene Beijing Co Ltd, Beijing, Peoples R China
[18] BeiGene USA Inc, San Mateo, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-566-148; 613-135-2370-7650-2700; 130-274-2403; 613-302-309; 613-302-312-303; 17; 9; 3; 2; 2424; 1704;
D O I：
10.1200/JCO.2024.42.3_suppl.290
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：290 / 290
页数：1
相关论文
共 50 条
  • [1] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
    Xu, R-H.
    Oh, D-Y.
    Kato, K.
    Arkenau, T.
    Tabernero, J.
    Cruz-Correa, M.
    Zimina, A.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Spigel, D. R.
    Wyrwicz, L. S.
    Cid, R. A. Pazo
    Li, L.
    Xu, Y.
    McHenry, M. B.
    Yang, S.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1320 - S1321
  • [2] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
    Xu, R-H.
    Oh, D-Y.
    Kato, K.
    Arkenau, H-T.
    Tabernero, J.
    Cruz-Correa, M.
    Zimina, A. V.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Spigel, D. R.
    Wyrwicz, L. S.
    Pazo Cid, R. A.
    Li, L.
    Xu, Y.
    McHenry, M. B.
    Yang, S.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1527
  • [3] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study
    Kato, K.
    Xu, R-H.
    Oh, D-Y.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Xu, H.
    Sheng, T.
    Barnes, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S1456 - S1456
  • [4] Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with/without peritoneal or liver metastases: A post hoc analysis of RATIONALE-305 study.
    Qiu, Miaozhen
    Luo, Huiyan
    Wang, Feng-Hua
    Wang, Feng
    He, Ming-Ming
    Xu, Sheng
    Pan, Xiaoxi
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 414 - 414
  • [5] Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
    Moehler, Markus H.
    Kato, Ken
    Arkenau, Hendrik-Tobias
    Oh, Do-Youn
    Tabernero, Josep
    Cruz-Correa, Marcia
    Wang, HongWei
    Xu, Hui
    Li, Jiang
    Yang, Silu
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 286 - 286
  • [6] Tislelizumab plus chemotherapy (chemo) versus placebo plus chemo as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup.
    Arkenau, Hendrik-Tobias
    Tabernero, Josep
    Cruz-Correa, Marcia
    Zimina, Anastasia V.
    Poddubskaya, Elena
    Moiseenko, Fedor Vladimirovich
    Spigel, David R.
    Wyrwicz, Lucjan S.
    Disel, Umut
    Pazo Cid, Roberto
    Cubillo Gracian, Antonio
    Ales Diaz, Inmaculada
    Fornaro, Lorenzo
    Evesque, Ludovic
    Xu, Yaling
    Sheng, Tao
    Yang, Silu
    Li, Liyun
    Moehler, Markus H.
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 330 - 330
  • [7] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses
    Lei, Ming
    Janjigian, Yelena Y.
    Ajani, Jaffer A.
    Moehler, Markus
    Wang, Xuya
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Tehfe, Mustapha
    Elimova, Elena
    Li, Mingshun
    Poulart, Valerie
    Wang, Yu
    Doshi, Parul
    Shitara., Kohei
    CANCER RESEARCH, 2022, 82 (12)
  • [8] Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
    Janjigian, Y. Y.
    Ajani, J. A.
    Moehler, M.
    Garrido, M.
    Gallardo, C.
    Shen, L.
    Yamaguchi, K.
    Wyrwicz, L.
    Skoczylas, T.
    Bragagnoli, A.
    Liu, T.
    Tehfe, M.
    Elimova, E.
    Li, M.
    Poulart, V.
    Lei, M.
    Kondo, K.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S1329 - S1330
  • [9] RATIONALE 305: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with gastric or gastroesophageal junction adenocarcinoma
    Xu, R.
    Arkenau, T.
    Bang, Y.
    Denlinger, C.
    Kato, K.
    Tabernero, J.
    Wang, J.
    Li, J.
    Castro, H.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S97 - S98
  • [10] Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
    Moehler, M.
    Shitara, K.
    Garrido, M.
    Salman, P.
    Shen, L.
    Wyrwicz, L.
    Yamaguchi, K.
    Skoczylas, T.
    Campos Bragagnoli, A.
    Liu, T.
    Schenker, M.
    Yanez, P.
    Tehfe, M.
    Poulart, V.
    Cullen, D.
    Lei, M.
    Kondo, K.
    Li, M.
    Ajani, J. A.
    Janjigian, Y. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1191 - S1191
12345